In this context, the optimization of methodologies aimed at producing a good manufacturing practice expansion of LTNK cells may lead to their clinical implementation in the therapy of AML.[1–3] Also, the inhibition of AML cell-induced STNK cell abnormalities by drug mimicking the effects of TIMP3 such as TAPI-0[26] on STNK cells may allow STNK cells to be utilized to fight AML disease. This evidence concerns the gene TIMP3 and acute myeloid leukemia.